News & Updates
Showing Pharmacy articles
Showing
Etanercept biosimilar demonstrates long-term safety, efficacy in rheumatoid arthritis
YLB113, a biosimilar of the reference product etanercept, appears to be safe for long-term treatment of patients with rheumatoid arthritis, with efficacy sustained for up to 96 weeks, according to a study. Notably, the biosimilar is associated with fewer cases of injection-site reactions and injection-site erythema compared with the reference.
Ritlecitinib, brepocitinib superior to placebo for inducing remission in UC
Ritlecitinib and brepocitinib as induction therapies for ulcerative colitis (UC) appear to be more effective than placebo while having an acceptable short-term safety profile, according to the results of a phase IIb study.
Regdanvimab for COVID-19 effective against Delta variant
The neutralizing antibody regdanvimab appears to be useful in the treatment of mild-to-moderate COVID-19, with a recent study showing that the drug may prevent disease worsening in patients, including those infected with the Delta variant.
Cardiovascular death among seniors with pneumonia down with antibiotic therapy
In the treatment of older patients hospitalized with community-acquired pneumonia, the use of guideline-concordant antibiotic therapy significantly lowers the risk of cardiovascular death in the first year of follow-up, as reported in a study.